Christiane S. Querfeld
Elite in Sezary Syndrome

Dr. Christiane S. Querfeld

Dermatology
City Of Hope Medical Foundation
1601 Avocado Ave, 
Newport Beach, CA 
Offers Telehealth
Elite in Sezary Syndrome
City Of Hope Medical Foundation
1601 Avocado Ave, 
Newport Beach, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christiane Querfeld is a Dermatologist in Newport Beach, California. Dr. Querfeld and is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 26 articles and participated in 2 clinical trials in the study of Sezary Syndrome.

Specialties
Dermatology
Licenses
Dermatology in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CITY OF HOPE MEDICAL FOUNDATION
1601 Avocado Ave, Newport Beach, CA 92660

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Durvalumab, Lenalidomide
Study Phase: Phase 1/Phase 2
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Drug: BNZ132-1-40
Study Phase: Phase 1/Phase 2
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

120 Total Publications

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 19, 2024
Similar Doctors
Distinguished in Sezary Syndrome
Dr. Farah R. Abdulla
Dermatology
Distinguished in Sezary Syndrome
Dr. Farah R. Abdulla
Dermatology
1500 Duarte Rd, 
Duarte, CA 
 (36.0 mi)
626-256-4673
Languages Spoken:
English
See accepted insurances

Farah Abdulla is a Dermatologist in Duarte, California. Dr. Abdulla and is rated as a Distinguished provider by MediFind in the treatment of Sezary Syndrome. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

Experienced in Sezary Syndrome
Dr. Timothy H. Almazan
Dermatology
Experienced in Sezary Syndrome
Dr. Timothy H. Almazan
Dermatology
11900 S St, Suite 118, 
Cerritos, CA 
 (20.9 mi)
562-246-6222
Languages Spoken:
English

Timothy Almazan is a Dermatologist in Cerritos, California. Dr. Almazan and is rated as an Experienced provider by MediFind in the treatment of Sezary Syndrome. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Prurigo Nodularis, and Acne.

Experienced in Sezary Syndrome
Dr. Wonwoo Shon
Dermatology
Experienced in Sezary Syndrome
Dr. Wonwoo Shon
Dermatology

Cedars-Sinai Medical Care Foundation

1 Technology Dr, Suite C523, 
Irvine, CA 
 (8.0 mi)
949-333-3661
Experience:
17+ years
Languages Spoken:
English
Offers Telehealth

Wonwoo Shon is a Dermatologist in Irvine, California. Dr. Shon has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Sezary Syndrome. His top areas of expertise are Pyogenic Granuloma, Merkel Cell Carcinoma, Melanoma, and Hemangioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Querfeld's expertise for a condition
ConditionClose
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile